Seamus Fernandez
Stock Analyst at Guggenheim
(4.54)
# 280
Out of 4,996 analysts
107
Total ratings
54.43%
Success rate
28.67%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Buy | $70 → $167 | $90.50 | +84.54% | 5 | Sep 25, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $44 → $84 | $17.51 | +379.73% | 3 | Sep 23, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $17 → $25 | $14.52 | +72.18% | 2 | Sep 15, 2025 | |
| TENX Tenax Therapeutics | Maintains: Buy | $15 → $14 | $7.26 | +92.84% | 2 | Aug 14, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $942 → $875 | $724.54 | +20.77% | 18 | Aug 13, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $92 → $90 | $25.00 | +260.00% | 2 | Aug 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $119 → $120 | $99.16 | +21.02% | 2 | Aug 6, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | $116 | $38.21 | +203.59% | 8 | Jul 2, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $17.57 | - | 3 | Apr 3, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $33.98 | +370.87% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $56 | $52.25 | +7.18% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $39.99 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $78.56 | +55.30% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $39.85 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.00 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $22.17 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $44.12 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $55.61 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $123.65 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.04 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $1.99 | +2,613.57% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $26.14 | +72.15% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $73.76 | -48.48% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $23.76 | +59.93% | 3 | Jan 31, 2018 |
Cidara Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $70 → $167
Current: $90.50
Upside: +84.54%
MBX Biosciences
Sep 23, 2025
Maintains: Buy
Price Target: $44 → $84
Current: $17.51
Upside: +379.73%
Amylyx Pharmaceuticals
Sep 15, 2025
Maintains: Buy
Price Target: $17 → $25
Current: $14.52
Upside: +72.18%
Tenax Therapeutics
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $7.26
Upside: +92.84%
Eli Lilly and Company
Aug 13, 2025
Maintains: Buy
Price Target: $942 → $875
Current: $724.54
Upside: +20.77%
Structure Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $92 → $90
Current: $25.00
Upside: +260.00%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $119 → $120
Current: $99.16
Upside: +21.02%
Apogee Therapeutics
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $38.21
Upside: +203.59%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $17.57
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $33.98
Upside: +370.87%
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $52.25
Upside: +7.18%
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $39.99
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $78.56
Upside: +55.30%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $39.85
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.00
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $22.17
Upside: -
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $44.12
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $55.61
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $123.65
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.04
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $1.99
Upside: +2,613.57%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $26.14
Upside: +72.15%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $73.76
Upside: -48.48%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $23.76
Upside: +59.93%